Nuvectis Pharma (NASDAQ: NVCT) insider transactions
In the twelve months to 10 November 2026, executives and directors of Nuvectis Pharma reported 0 open-market sales and 2 open-market purchases of 62,500 shares ($1.2m), by 2 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 3 August 2026 | Carson Michael J. | Vice President, Finance | Grant or award | +30,000 | — | 230,118 | Form 4 |
| 30 June 2026 | Bentsur Ron | Chairman & CEO | Open-market purchase | +12,500 | $20.00 | 3,688,424 | Form 4 |
| 30 June 2026 | Mosseri Marlio Charles | — | Open-market purchase | +50,000 | $18.32 | 3,186,576 | Form 4 |
| 11 June 2026 | Kaplan Matthew L. | Director | Grant or award | +35,000 | — | 159,760 | Form 4 |
| 11 June 2026 | Sanchez Juan | Director | Grant or award | +35,000 | — | 113,380 | Form 4 |
| 11 June 2026 | Oliviero James F III | Director | Grant or award | +35,000 | — | 122,828 | Form 4 |
| 11 June 2026 | Hoberman Kenneth | Director | Grant or award | +35,000 | — | 168,140 | Form 4 |
| 6 January 2026 | Carson Michael J. | Vice President, Finance | Grant or award | +61,200 | — | 200,118 | Form 4 |
| 6 January 2026 | Poradosu Enrique | Chief Science & Business Off | Grant or award | +150,000 | — | 1,806,319 | Form 4 |
| 6 January 2026 | Bentsur Ron | Chairman & CEO | Grant or award | +150,000 | — | 3,675,924 | Form 4 |
| 6 January 2026 | Shemesh Shay | Chief Dev. & Ops. Officer | Grant or award | +150,000 | — | 1,793,068 | Form 4 |
| 5 November 2025 | Kaplan Matthew L. | Director | Open-market purchase | +11,000 | $5.84 | 124,760 | Form 4 |
| 5 November 2025 | Sanchez Juan | Director | Open-market purchase | +13,000 | $5.79 | 78,150 | Form 4 |
| 5 November 2025 | Bentsur Ron | Chairman & CEO | Open-market purchase | +5,000 | $5.72 | 3,525,924 | Form 4 |
| 27 October 2025 | Mosseri Marlio Charles | — | Open-market purchase | +72,836 | $6.28 | 3,136,576 | Form 4 |
| 24 October 2025 | Mosseri Marlio Charles | — | Open-market purchase | +35,034 | $6.15 | 3,063,740 | Form 4 |
| 23 October 2025 | Mosseri Marlio Charles | — | Open-market purchase | +46,900 | $6.06 | 3,028,706 | Form 4 |
| 22 September 2025 | Sanchez Juan | Director | Grant or award | +30,000 | — | 65,150 | Form 4 |
| 20 June 2025 | Mosseri Marlio Charles | — | Open-market purchase | +5,603 | $7.99 | 2,981,806 | Form 4 |
| 18 June 2025 | Mosseri Marlio Charles | — | Open-market purchase | +28,043 | $8.05 | 2,976,203 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Nuvectis Pharma page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.